- Research article
- Open Access
Antagonistic effect of Lactobacillusstrains against gas-producing coliforms isolated from colicky infants
© Savino et al; licensee BioMed Central Ltd. 2011
- Received: 4 January 2011
- Accepted: 30 June 2011
- Published: 30 June 2011
Infantile colic is a common disturb within the first 3 months of life, nevertheless the pathogenesis is incompletely understood and treatment remains an open issue. Intestinal gas production is thought to be one of the causes of abdominal discomfort in infants suffering from colic. However, data about the role of the amount of gas produced by infants' colonic microbiota and the correlation with the onset of colic symptoms are scanty. The benefit of supplementation with lactobacilli been recently reported but the mechanisms by which they exert their effects have not yet been fully defined. This study was performed to evaluate the interaction between Lactobacillus spp. strains and gas-forming coliforms isolated from stools of colicky infants.
Strains of coliforms were isolated from stools of 45 colicky and 42 control breastfed infants in McConkey Agar and identified using PCR with species-specific primers, and the BBL™ Enterotube™ II system for Enterobacteriaceae. Gas-forming capability of coliforms was assessed in liquid cultures containing lactose as sole carbon source. The average count of total coliforms in colicky infants was significantly higher than controls: 5.98 (2.00-8.76) log10 vs 3.90 (2.50-7.10) CFU/g of faeces (p = 0.015). The following strains were identified: Escherichia coli, Klebsiella pneumoniae, Klebsiella oxytoca, Enterobacter aerogenes, Enterobacter cloacae and Enterococcus faecalis. Then, 27 Lactobacillus strains were tested for their antagonistic effect against coliforms both by halo-forming method and in liquid co-cultures. Lactobacillus delbrueckii subsp.delbrueckii DSM 20074 and L. plantarum MB 456 were able to inhibit all coliforms strains (halo-forming method), also in liquid co-cultures, thus demonstrating an antagonistic activity.
This study shows that two out of 27 strains of Lactobacillus examined possess an antimicrobial effect against six species of gas-forming coliforms isolated from colicky infants. Our findings may stimulate new researches to identify which Lactobacillus strains can improve colicky symptoms by acting on coliforms gut colonization.
- Lactic Acid Bacterium
- Luria Bertani
- Total Coliform
- Lactobacillus Strain
The intestinal microbiota exerts many physiological functions such as metabolic and trophic activities and plays an important role in the "barrier effect" against exogenous microbes . It is also involved in the development and activation of the intestinal immune system: a recent study suggests that a more diverse gut microbiota early in life might prevent allergy development . Gut microbiota is acquired during early life and intestinal colonization starts immediately after birth. The ability of species to establish themselves durably in the colonic ecosystem depends on complex interactions between host and bacteria as well as between the bacteria themselves . A wide range of factors may influence the establishment of the intestinal microbiota, including type of delivery, feeding pattern, antibiotic therapy, contact with parents, siblings and hospital staff . The nature of the gut flora, colonic bacterial metabolic pathways, the partial pressure of hydrogen in the colon, the buffering capacity of the colon, and incomplete monosaccharide absorption may play a part in infantile colic. Miller reported an increased breath hydrogen excretion in subjects suffering from infantile colic . In 1994, Lehtonen et al. observed that an inadequate lactobacilli level occurring in the first months of life may affect the intestinal fatty acids profile and could favour the development of infantile colic . Treem suggested that colicky infants produce large amounts of gas probably by colonic bacterial fermentation of malabsorbed dietary carbohydrate and that they are relieved of symptoms by the passage of gas . It has also been demonstrated that less methane is produced by stool of colicky infants and this could be due to an inability of the gut microbiota to convert hydrogen to methane with a gastrointestinal hydrogen accumulation . Moreover few old data support the notion that colicky infants produce more breath hydrogen in the fasting state and in response to feedings, which is thought to be evidence of lactose intolerance [9–11].
Differences in gut microbiota have been found among colicky and non-colicky infants: colicky infants are less frequently colonized by Lactobacillus spp. and more frequently by anaerobic gram-negative bacteria . Further, different colonization patterns of lactobacilli have been found among colicky and healthy infants: L. brevis and L. lactis are present only in colicky infants while L. acidophilus was detected only in healthy ones .
The recent finding that L. reuteri improve colic symptoms in breastfed infants suggested that a peculiar composition of the intestinal microbiota could favour the development of such disturbance [14, 15]; however the mechanisms through which lactic acid bacteria act on colic symptoms remain speculative. Moreover, our recent study evaluated the colonization pattern of some important gas-forming coliforms in colicky infants and healthy controls through molecular methods: coliform bacteria, in particular Escherichia coli, resulted more abundant in infants with infantile colic, reinforcing the concept that gut microbiota could be implicated in the aetiopathogenesis of the disturbance [16, 17]. Nevertheless, up today, little is known about the role of the amount of gas produced by infants' colonic microbiota and the correlation with the onset of colic symptoms, even thought intestinal gas is though to be one of the causes of abdominal discomfort.
This study was performed to elucidate the interaction between lactobacilli and gas-forming coliforms in the gut. To this aim, 27 Lactobacillus strains were examined for their potential in-vitro anti-microbial activity against gas-forming coliforms isolated from stools of colicky infants.
Study group and sample collection
Clinical characteristics of the study population and count of total coliforms bacteria
Colicky infants (n = 45)
Controls (n = 42)
Age at recruitment (days)
Type of delivery (spontaneous/caesarean)
Birth weight (grams)
Crying time (minutes per day)
Average count of total coliform bacteria (log10 CFU/g of faeces)
Isolation and identification of coliforms
Faecal samples, collected from all infants, were homogenized (10%, w/v) with sterile saline (0.9% NaCl). The homogenates were filtered through a 100 μm metal sieve and serially diluted in saline. One hundred μl of each dilution were plated on selective MacConkey Agar (BD Italia, Milan, Italy), which is widely used to isolate enteric bacteria and as a presumptive test for coliform organisms  and plates were incubated overnight at 37°C in 5% CO2 atmosphere. All colonies were counted and counts expressed as log10 colony-forming units (CFU) per g of faeces. Each isolated strain was subcultured at 37°C for 18 h in Luria Bertani medium (LB)  under microaerophilic conditions. Identification of the isolated strains was performed by using the polymerase chain reaction (PCR) technique followed by sequencing of the amplified sequences and the BBL™ Enterotube™ II system, which allows the identification of Enterobacteriaceae on the basis of selective carbohydrate fermentation, gas production and the response to selective biochemical reactions (Becton Dickinson GmbH, Heidelberg, Germany). PCR was performed as follows: each isolated strain was streaked on a LB plate, which was incubated overnight at 37°C. A single colony of each strain was picked and suspended in 20 μl of sterile distilled water; the cell suspension was heated at 95°C for 10 min and then cooled to 4°C. The rDNA fragment comprising the internal transcribed spacer and the flanking 16S and 23S rDNA regions was amplified by using the primers indicated in a previous paper  and a Biometra (M-Medical SrL, Milan, Italy) thermocycler; the amplified fragments were sequenced and aligned with the most similar ones of GenBank using the Basic Local Alignment Search Tool (BLAST) program.
Evaluation of the gas-forming capability of the isolated strains
The gas-forming capability of the strains isolated from stool samples was assessed in Lauryl sulphate tryptose broth containing lactose (10 g/L) as the sole carbon source. After inoculum and incubation for 24-48 h at 37°C, bacterial cultures were examined for the presence of gas bubbles in the medium . Production of gas indicated a positive reaction.
Lactobacillusstrains and culture conditions
Lactobacillus strains tested for their antagonist activity against coliforms isolated from colicky infants
ATCC 11975; MB 252; MB 253; MB 358; MB 359; MB 422; MB 423; MB 424; MB 425; MB 442; MB443
MB 67; MB 68
ATCC 393; MB 50; MB 441
L. delbrueckii subsp.delbrueckii
L. delbrueckii subsp.lactis
L. delbrueckii subsp.bulgaricus
L. salivarius subsp.salicinius
L. salivarius subsp.salivarius
S 36.2; S40.8
ATCC 8014; NCDO 1193; MB 456
Assessment of the antagonistic activity
The antagonistic activity of the selected Lactobacillus strains against the isolated coliforms was assayed by using both agar plates and liquid co-cultures of both strains.
- Antimicrobial activity on agar plates
In this assay both Lactobacillus spp. cells and Lactobacillus neutralized cell-free supernatants (NCS) were employed. Each Lactobacillus strain was grown in MRS broth for 48 h at 37°C in 5% CO2 atmosphere and then centrifuged at 15000 g at 4°C for 15 minutes. pH of the cultures was neutralized to pH 7 with 1N NaOH and cells were separated through filtration (via a 0.2 μm pore size filter). Lactobacillus cells were washed twice with saline and suspended in saline at concentrations ranging from 104 to 106 CFU/ml. Lactobacillus cells were washed twice with saline and suspended in saline at concentrations of 104 , 105 and 106 CFU/ml. All the cell suspensions were assayed to optimize the most suitable cell concentration; the cell concentration of 106 CFU/ml was then used to perform the comparative assay of the inhibitory activity of the two Lactobacillus strains against coliforms. The paper-disk assay of Kirby-Bauer  was used with some modifications as follows. 50 μl of coliform liquid culture in LB broth containing from 103 to 106 CFU/ml, in the majority of cases between 105 and 106, was streaked on a Mac Conkey and LB agar plate; subsequently two sterile paper blank disks (diameter 6 mm) were placed on the agar plate and imbibed one with 50 μl of washed Lactobacillus cells and the other with 50 μl of the corresponding NCS. After incubation for 18 h at 37°C, the diameters of the inhibition zones were evaluated. The experiments were made in triplicate.
- Antimicrobial activity in liquid co-cultures
The capability of Lactobacillus DSM 20074 of interfering with the growth of coliforms was evaluated by co-incubating both strains. The Lactobacillus strains and the coliform strains were grown on MRS broth and LB broth, respectively. The co-culture experiments was performed in a modified LB medium (i.e. LB additioned with 3% w/v yeast extract) capable of sustaining the growth of both microorganisms. The medium was inoculated with 105 CFU/ml of both the Lactobacillus and the coliform strains and incubated at 37°C in microaerophylic conditions. Controls were prepared by inoculating the same medium either with the Lactobacillus strain or with the coliform one; in addition coliforms were co-cultured with a Lactobacillus strain with no inhibition activity (L. casei MB50, Table 2). At 8-10 h intervals, cultures were centrifuged for 15 min at 5000 g and pellets were resuspended in fresh modified LB medium to limit changes in growth due to pH variation or nutrient limitation. 24 and 48 h after inoculation, bacterial cells were collected and thoroughly resuspended by vortexing in phosphate-buffered saline (PBS). Thereafter, Lactobacillus and coliform concentrations in the co-cultures and in the controls was determined on MRS agar plates additioned with vancomycin (0.2% w/v) and MacConkey agar plates, which are selective for Lactobacillus spp. and coliforms, respectively. Antimicrobial activity was calculated by comparing the coliform growth in the co-culture and control . Results were expressed as log10 CFU/ml. The experiment was performed in triplicate.
Sample size was calculated based on a difference between groups of 1.5 log10 CFU/g faeces. Using α = 0.05, β = 0.20 and an estimated standard deviation within groups of 2 log10 CFU/g faeces, 30 patients were needed in each group. Counts (log10 CFU/g) of the total amount of coliform bacteria were calculated for each stool sample. Data are summarized by counts and median and range for categorical and continuous variables respectively. Differences between groups were evaluated with Mann-Whitney's U-test for continuous variables, whereas associations between categorical variables were evaluated with Fisher's exact test. Differences between colicky infants and controls in total amount of each species detected were evaluated with Mann-Whitney's test with Bonferroni correction. Statistical significance was set at a p-value < 0.05. All statistical calculations were performed with commercially available software (SPSS for Windows release 15Æ0 SPSS Inc., Chicago, IL, USA).
Isolation and identification of coliforms from colicky infants
Identification of the strains isolated from faeces of colicky infants at the species level and % of each species of the total colonies isolated from the faeces examined
Quantitative detection (%)
Antimicrobial activity of lactic acid bacteria against coliforms
Antagonistic activity of L. delbrueckii DSM 20074 and L. plantarum MB 456 cell suspensions (106 CFU/ml) against coliforms isolated from colicky infants
Average diameter of the inhibition halo in mm (average ± SD)
L. delbrueckiiDSM 20074
L. plantarumMB 456
E. coli CG 15b
10.23 ± 1.29
8.33 ± 0.89
K. oxytoca GC Y
9.75 ± 1.06
7.75 ± 0.76
K. pneumoniae CG 23a
9.83 ± 1.04
9.83 ± 0.64
E. faecalis GC W
10.16 ± 0.76
8.16 ± 0.56
E. aerogenes GC K
10.25 ± 0.65
7.25 ± 0.25
E. cloacae CG 6a
10.25 ± 0.35
7.05 ± 0.35
The anti-microbial activity evaluation in liquid co-cultures was performed with the Lactobacillus strain showing the highest anti-microbial activity with the previous method, i.e. L. delbrueckii subsp.delbrueckii DSM 20074, and each of the strains referred to the six species of coliform found. Inhibitory activity was evidenced against all the six coliform strains, being higher with the E. coli CG 15b strain. Referring to the experiment with DSM 20074 and E. coli CG 15b strains, the co-culture at the beginning of the incubation time contained 5.43 ± 0.54 log10 CFU/ml of L. delbrueckii DSM 20074 and 5.70 ± 0.35 log10 CFU/ml of E. coli CG 15b. After 24 h of incubation, the DSM 20074 concentration was increased to 9.84 ± 0.94 log10 CFU/ml, whereas no variations were observed in the E. coli count. In the parallel control experiment, in which E. coli was cultivated with no other strain, the E. coli concentration was 5.65 ± 0.34 and 9.00 ± 1.00 log10 CFU/ml at the beginning of the incubation and after 24 hours, respectively. When E. coli was co-cultured with L. casei MB50, no inhibition of E. coli growth was observed. In the co-culture experiments performed with L. delbrueckii DSM20074 and the other coliform strains listed in Table 3, an inhibition of the coliform growth of 3-4 log10 CFU/ml was observed (data not shown). On the other hand, the growth of the Lactobacillus strain was never influenced by co-cultivation with the coliform strains.
Different studies suggested that colonic gas production favours infantile colic, however the speculation is not supported by well-built scientific researches. Recently, it has been evidenced that gas forming coliform concentration is higher in colicky infants than in healthy controls . Various medical interventions have already been applied to improve symptoms related to infantile colic. Simethicone, a defoaming agent, has been promoted as an effective treatment reducing the formation of intraluminal gas, even though existing data do not demonstrate conclusive benefit of such therapy [24, 25]. Alternative solutions to the problem are therefore looked forward.
Recently the benefit of supplementation with Lactobacillus reuteri (American Type Culture Collection Strain 55730 and DSM 17 938) has been reported opening a new therapeutic approach [14, 15], even though clinical trials are needed to promote new treatments to reduce abdominal pain related to infantile colic .
Coliform growth and carbohydrate fermentation affect ammonia absorption and urea nitrogen recycling and excretion. We observed reduction in fecal ammonia concentrations in breastfed infants given L. reuteri and this could be related to modification of bacterial enzyme activity depending on gut microbiota and suggested that gas forming coliforms may be involved in determining colonic fermentation and consequently excessive intraintestinal air load, aerophagia and pain, characteristic symptoms of colic crying, but many aspects of these relationships are still unclear . In the present study we confirmed the higher count of coliforms in colicky infants with respect to non colicky newborns, as already observed in a previous work .
Previous studies had shown that some Lactobacillus spp. strains possessed inhibitory activity against E. coli, preventing the binding of enteropathogenic E. coli and other pathogens to intestinal cells . More recently it has been shown that a synbiotic diet containing both prebiotics and probiotics reduces population of intestinal E. coli and the pathogen population in rats .
Given these findings, in this work new Lactobacillus strains possessing anti-microbial activity against gas-producing coliforms were searched and the interaction between selected lactobacilli and coliforms was studied.
Coliforms were isolated from stools of colicky infants and characterized taxonomically and for gas production. They were all gas-producing strains and were attributed to 6 different species. The taxonomic identification of the isolated strains and their relative percentage within the coliform group confirmed the results obtained in a previous study, being E. coli the most represented species . Two of the 27 lactic acid bacteria assayed in this study, L. delbrueckii subsp.delbrueckii DSM 20074 and L. plantarum MB 456, were able to inhibit the growth of gas-forming coliforms belonging to the different species isolated from colicky infants. The extent of the inhibitory activity was similar for all the coliforms assayed (Table 4), although it was higher for the DSM 20074 strain with respect to the other one. Moreover, the capability of the DSM 20074 strain of hindering the growth of coliforms was also observed in a liquid co-culturing assay. Therefore, this strain appears to be a good candidate to relieve symptoms caused by gas-producing coliforms in colicky infants.
The antagonistic activity of the two Lactobacillus strains was only evidenced when harvested cells were applied, whereas the neutralized culture supernatants did not exert any activity on the same coliforms (Figure 1). The inhibitory activity of lactic acid bacteria has generally been ascribed to two mechanisms, which can often coexist: i) the production of bacteriocins or bacteriocin-like molecules, which are very often secreted outside the cell [28, 29] and ii) the production of inhibitory non proteinaceous metabolites such as organic acids, carbon dioxide, ethanol, hydrogen peroxide and diacetyl, whose anti-microbial action is well known . In addition, Alakomi et al. reported that lactic acid can permeabilize the membrane of Gram negative bacteria by a mechanism of outer membrane disruption . In the case of the two lactic acid bacteria showing inhibitory activity against coliforms in this work, this activity is linked to the presence of the whole cells, although it is not possible to exclude that putative inhibitory molecules are present in the supernatants at such a low concentration that their activity cannot be detected by the assay employed. Therefore, it is not possible to clearly ascribe the inhibitory activity to a defined group of molecules and further studies are necessary to characterize the exact mechanism of inhibition.
In conclusion, this study confirmed the presence of a greater amount of coliforms in colicky infants with respect to the controls, mainly belonging to the E. coli species.
L. delbrueckii subsp.delbrueckii DSM 20074 strain expressed potential for the inhibition of gas-producing coliforms, and thus can be considered a promising candidate for the treatment of colicky symptoms in infants. At present, few data are available on the role of probiotics in colic and the mechanisms by which probiotic bacterial strains antagonise pathogenic gastrointestinal microorganisms or exert other beneficial effects in vivo have not yet been fully defined. Even so, there is a growing interest within clinical medicine in the understanding of the mechanisms through which lactic acid bacteria exert their antagonistic activity against pathogens in the gut. Finally, clinical investigations about in-vivo efficacy are necessary to confirm the role of Lactobacillus strains as efficacious probiotic treatment to modulate the colonic microbiota in newborns and improve abdominal discomfort due to infantile colic.
We are grateful to Roberto Calabrese for his help in statistical analysis.
- Guarner F: Enteric flora in health and disease. Digestion. 2006, 73: 5-12. 10.1159/000089775.PubMedView ArticleGoogle Scholar
- Sjögren YM, Tomicic S, Lundberg A, Böttcher MF, Björkstén B, Sverremark-Ekström E, Jenmalm MC: Influence of early gut microbiota on the maturation of childhood mucosal and systemic immune responses. Clin Exp Allergy. 2009, 39: 1842-51. 10.1111/j.1365-2222.2009.03326.x.PubMedView ArticleGoogle Scholar
- Penders J, Thijs C, Vink C, Stelma FF, Snijders B, Kummeling I, van den Brandt PA, Stobberingh EE: Factors influencing the competition of intestinal microbiota in early infancy. Pediatrics. 2006, 118: 511-21. 10.1542/peds.2005-2824.PubMedView ArticleGoogle Scholar
- Adlerberth I, Wold AE: Establishment of the gut microbiota in Western infants. Acta Paediatr. 2009, 98: 229-38. 10.1111/j.1651-2227.2008.01060.x.PubMedView ArticleGoogle Scholar
- Miller JJ, Mc Veagh P, Fleet GH, Petocs P, Brand JC: Breath hydrogen excretion in infants with colic. Arch Dis Child. 1989, 64: 725-9. 10.1136/adc.64.5.725.PubMedPubMed CentralView ArticleGoogle Scholar
- Lehtonen L, Korvenranta H, Eerola E: Intestinal microflora in colicky and non-colicky infants: bacterial cultures and gas-liquid chromatography. J Pediatr Gastroenterol Nutr. 1994, 19: 310-4. 10.1097/00005176-199410000-00009.PubMedView ArticleGoogle Scholar
- Treem WR: Infant colic: a pediatric gastroenterologist's perspective. Pediatr Clin North Am. 1994, 41: 1121-38.PubMedGoogle Scholar
- Belson A, Shetty AK, Yorgin PD, Bujanover Y, Peled Y, Dar MH, Reif S: Colonic Hydrogen elimination and methane production in infants with and without colic syndrome. Dig Dis Sci. 2003, 48: 1762-76. 10.1023/A:1025595029795.PubMedView ArticleGoogle Scholar
- Moore DJ, Robb TA, Davidson GP: Breath hydrogen response to milk containing lactose in colicky and non-colicky infants. J Pediatr. 1988, 113: 979-84. 10.1016/S0022-3476(88)80567-5.PubMedView ArticleGoogle Scholar
- Miller JJ, Brand JC, McVeagh P: Breath hydrogen excretion in infants with colic. Arch Dis Child. 1990, 65: 248-PubMedPubMed CentralView ArticleGoogle Scholar
- Kanabar D, Randhawa M, Clayton P: Improvement of symptoms in infant colic following reduction of lactose load with lactase. J Hum Nutr Diet. 2001, 14: 359-63. 10.1046/j.1365-277X.2001.00304.x.PubMedView ArticleGoogle Scholar
- Savino F, Cresi F, Pautasso S, Palumeri E, Tullio V, Roana J, Silvestro L, Oggero R: Intestinal microflora in breastfed colicky and non-colicky infants. Acta Paediatr. 2004, 93: 825-9. 10.1111/j.1651-2227.2004.tb03025.x.PubMedView ArticleGoogle Scholar
- Savino F, Bailo E, Oggero R, Tullio V, Roana J, Carlone N, Cuffini AM, Silvestro L: Bacterial counts of intestinal Lactobacillus species in infants with colic. Pediatr Allergy Immunol. 2005, 16: 72-5. 10.1111/j.1399-3038.2005.00207.x.PubMedView ArticleGoogle Scholar
- Savino F, Pelle E, Palumeri E, Oggero R, Miniero R: Lactobacillus reuteri (American Type Culture Collection Strain 55730) versus simethicone in the treatment of infantile colic: a prospective randomized study. Pediatrics. 2007, 119: e124-30. 10.1542/peds.2006-1222.PubMedView ArticleGoogle Scholar
- Savino F, Cordisco L, Tarasco V, Palumeri E, Calabrese R, Oggero R, Roos S, Matteuzzi D: Lactobacillus reuteri DSM 17938 in infantile colic: a randomized, double-blind, placebo-controlled trial. Pediatrics. 2010, 126: e526-33. 10.1542/peds.2010-0433.PubMedView ArticleGoogle Scholar
- Savino F, Tarasco V: New treatments for infantile colic. Curr Opin Pediatr. 2010, 22: 791-797. 10.1097/MOP.0b013e32833fac24.PubMedView ArticleGoogle Scholar
- Savino F, Cordisco L, Tarasco V, Calabrese R, Palumeri E, Matteuzzi D: Molecular identification of coliform bacteria from colicky breastfed infants. Acta Paediatr. 2009, 98: 1582-8. 10.1111/j.1651-2227.2009.01419.x.PubMedView ArticleGoogle Scholar
- Jiang T, Suarez FL, Levitt MD, Nelson SE, Ziegler EE: Gas production by feces of infants. J Pediatr Gastroenterol Nutr. 2001, 32: 534-41. 10.1097/00005176-200105000-00009.PubMedView ArticleGoogle Scholar
- Penders J, Vink C, Driessen C, London N, Thijs C, Stobberingh EE: Quantification of Bifidobacterium spp., Escherichia coli and Clostridium difficile in faecal samples of breast-fed and formula-fed infants by real-time PCR. FEMS Microbiol Lett. 2005, 243: 141-7. 10.1016/j.femsle.2004.11.052.PubMedView ArticleGoogle Scholar
- Wessel MA, Cobb JC, Jackson EB, Harris GS, Detwiler AC: Paroxismal fussing in infancy, sometimes called "colic". Pediatrics. 1954, 14: 421-35.PubMedGoogle Scholar
- Nakamura N, Gaskins HR, Collier CT, Nava GM, Rai D, Petschow B: Molecular ecological analysis of fecal bacterial populations from term infants fed formula supplemented with selected blends of probiotics. Appl Environ Microbiol. 2009, 75: 1121-8. 10.1128/AEM.02359-07.PubMedPubMed CentralView ArticleGoogle Scholar
- Sambrook J, Fritsch EF, Maniatis T: Molecular Cloning: A Laboratory Manual. 1989, New York: Cold Spring Harbor Laboratory Press, 2Google Scholar
- Bauer AW, Kirby WMM, Sherris JC, Turck M: Antibiotic susceptibility testing by a standardized single disk method. Am J Clin Pathol. 1966, 45: 493-6.PubMedGoogle Scholar
- Garrison MM, Christakis DA: A systematic review of treatments for infant colic. Pediatrics. 2000, 106: 184-90.PubMedGoogle Scholar
- Lucassen PL, Assendelft WJ, Gubbels JW, van Eijk JT, van Geldrop WJ, Neven AK: Effectiveness of treatments for infantile colic: systematic review. BMJ. 1998, 316: 1563-9.PubMedPubMed CentralView ArticleGoogle Scholar
- Servin AL: Antagonistic activities of lactobacilli and bifidobacteria against microbial pathogens. FEMS Microbiol Rev. 2004, 28: 405-40. 10.1016/j.femsre.2004.01.003.PubMedView ArticleGoogle Scholar
- Liong MT, Shah NP: Effects of a Lactobacillus casei synbiotic on serum lipoprotein, intestinal microflora, and organic acids in rats. J Dairy Sci. 2006, 89: 1390-9. 10.3168/jds.S0022-0302(06)72207-X.PubMedView ArticleGoogle Scholar
- Vandenbergh PA: Lactic acid bacteria, their metabolic products and interference with microbial growth. FEMS Microbiol Rev. 1993, 12: 22-38.Google Scholar
- Santini C, Baffoni L, Gaggìa F, Granata M, Gasbarri R, Di Gioia D, Biavati B: Characterization of probiotic strains: an application as feed additives in poultry against Campylobacter jejuni. Int J Food Microbiol. 2010, 141: S98-S108.PubMedView ArticleGoogle Scholar
- Galvez A, Abriouel H, Benomar N, Lucas R: Microbial antagonists to food-borne pathogens and biocontrol. Curr Op Biotechnol. 2010, 21: 142-8. 10.1016/j.copbio.2010.01.005.View ArticleGoogle Scholar
- Alakomi HL, Skytta E, Saarela M, Mattila-Sandholm T, Latva-Kala K, Helamder IM: Lactic acid permeabilizes Gram-negative bacteria by disrupting the outer membrane. Appl Environ Microbiol. 2000, 66: 2001-5. 10.1128/AEM.66.5.2001-2005.2000.PubMedPubMed CentralView ArticleGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.